Compare Danaher Corporation (DHR) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Linde PLC — how do they compare? Danaher Corporation trades at $199.47 (market cap $140.88B), while Linde PLC trades at $521.43 (market cap $241.59B). The key difference: Linde PLC is the larger of the two by market cap, and Linde PLC pays the higher dividend (1.22%). Which is the better fit depends on your goals.
| DHR | LIN | |
|---|---|---|
Market Cap | $140.88B | $241.59B |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $546.64 |
52-Week Low | $161.91 | $389.38 |
Enterprise Value | $153.66B | $263.95B |
Dividend Yield | 0.8% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Linde (LIN) trades at $522.54, down 1.37% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $560. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a net income margin of 20.44%. Recent news highlights sustainability leadership and strategic growth, though valuation ratios like a P/E of 34.75 suggest premium pricing.
The stock offers steady growth potential driven by earnings beats and dividend consistency, but faces risks from rising debt levels and macroeconomic pressures. Analyst sentiment is overwhelmingly bullish with 85.7% buy ratings, indicating confidence in Linde's operational strength and future performance, though investors should monitor debt trends and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
